Karin Sennfalt

Summary

Country: Sweden

Publications

  1. ncbi Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden
    K Sennfalt
    Center for Medical Technology Assessment, University of Linkoping, Sweden
    Scand J Gastroenterol 36:870-6. 2001
  2. ncbi Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Perit Dial Int 22:39-47. 2002
  3. ncbi Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Lars Bernfort
    Centre for Medical Technology Assessment, University of Linkoping, Stockholm, Sweden
    Scand J Infect Dis 38:497-505. 2006
  4. ncbi Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Linkoping, Sweden
    Scand J Urol Nephrol 38:291-8. 2004
  5. ncbi The estimated economic value of the welfare loss due to prostate cancer pain in a defined population
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Acta Oncol 43:290-6. 2004
  6. ncbi Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Eur Urol 49:1028-34. 2006
  7. ncbi Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University Hospital, Sweden
    Scand J Urol Nephrol 37:226-31. 2003

Detail Information

Publications7

  1. ncbi Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden
    K Sennfalt
    Center for Medical Technology Assessment, University of Linkoping, Sweden
    Scand J Gastroenterol 36:870-6. 2001
    ..Combination therapy, however, is two to three times as expensive as monotherapy...
  2. ncbi Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Perit Dial Int 22:39-47. 2002
    ..Our aim was to compare both health-related quality of life and costs for hemodialysis (HD) and peritoneal dialysis (PD) in a defined population...
  3. ncbi Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Lars Bernfort
    Centre for Medical Technology Assessment, University of Linkoping, Stockholm, Sweden
    Scand J Infect Dis 38:497-505. 2006
    ..The cost-effectiveness for patients infected with genotype 2/3 was less obvious...
  4. ncbi Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Linkoping, Sweden
    Scand J Urol Nephrol 38:291-8. 2004
    ..To estimate the lifetime cost per detected potentially curable cancer and the economic impact on healthcare of repeated screening for prostate cancer in Sweden in a cohort of men aged 50-69 years...
  5. ncbi The estimated economic value of the welfare loss due to prostate cancer pain in a defined population
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Acta Oncol 43:290-6. 2004
    ..Based on an estimate of the willingness to pay for a QALY the economic value of this welfare loss due to prostate cancer pain is in the magnitude of Euro 86 600 000 per year (Euro 19 800000 per million men in Sweden)...
  6. ncbi Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University, Sweden
    Eur Urol 49:1028-34. 2006
    ..To describe the diffusion of six main health technologies used for management of prostate cancer, to estimate the economic consequences of technological changes, and to explore factors behind the diffusion...
  7. ncbi Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population
    Karin Sennfalt
    Center for Medical Technology Assessment, Linkoping University Hospital, Sweden
    Scand J Urol Nephrol 37:226-31. 2003
    ..The aim was to calculate direct costs for the management of prostate cancer, describe the economic consequences of technological changes over time and estimate total direct costs for prostate cancer in Sweden...